ELEX BIOTECH, LLC

Basic Information

2828 SW CORBETT AVE, STE 140A
PORTLAND, OR, 97201-4830

http://www.elexbiotech.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 832476803
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Development of novel compounds for the treatment of atrial fibrillation

    Amount: $427,638.00

    DESCRIPTION provided by applicant Atrial fibrillation AF is the most prevalent type of cardiac arrhythmia in the developed world affecting million people in the United States alone a number t ...

    STTR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

    Amount: $750,385.00

    DESCRIPTION provided by applicant Abstract Current therapies to treat the orphan disease catecholaminergic polymorphic ventricular tachycardia CPVT have potential side effects so severe that ho ...

    STTR Phase II 2015 Department of Health and Human Services National Institutes of Health
  3. Rational Design of New Drugs to Treat Ventricular Arrhythmias

    Amount: $349,774.00

    DESCRIPTION (provided by applicant): Sudden cardiac death (SCD) is a major cause of death, responsible for greater than 300,000 adult deaths per year in the United States alone. Cardiac arrest and SCD ...

    STTR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government